


Clozapine N-oxide

Cat. No.:	HY-17366		
CAS No.:	34233-69-7		
Molecular Formula:	C ₁₈ H ₁₉ ClN ₄ O		
Molecular Weight:	342.82		
Target:	mAChR; Drug Metabolite; Dopamine Receptor		
Pathway:	GPCR/G Protein; Neuronal Signaling; Metabolic Enzyme/Protease		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	1 year
		-20°C	6 months



SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (291.70 mM; Need ultrasonic)
 H₂O : 1 mg/mL (2.92 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
	1 mM	2.9170 mL	14.5849 mL	29.1698 mL
	5 mM	0.5834 mL	2.9170 mL	5.8340 mL
	10 mM	0.2917 mL	1.4585 mL	2.9170 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
Solubility: ≥ 2.5 mg/mL (7.29 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (7.29 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.5 mg/mL (7.29 mM); Clear solution
- Add each solvent one by one: PBS
Solubility: 2.44 mg/mL (7.12 mM); Clear solution; Need ultrasonic and warming and heat to 60°C
- Add each solvent one by one: 5% DMSO >> 40% PEG300 >> 5% Tween-80 >> 50% saline
Solubility: ≥ 0.5 mg/mL (1.46 mM); Clear solution
- Add each solvent one by one: 5% DMSO >> 95% (20% SBE-β-CD in saline)
Solubility: ≥ 0.5 mg/mL (1.46 mM); Clear solution

BIOLOGICAL ACTIVITY

Description	Clozapine N-oxide is a major metabolite of Clozapine and a human muscarinic designer receptors (DREADDs) agonist. Clozapine N-oxide activates the DREADD receptor hM3Dq and hM4Di. Clozapine N-oxide can cross the blood-brain barrier [1][2][3][4]. Clozapine is a potent dopamine antagonist and also a potent and selective muscarinic M4 receptor (EC ₅₀ =11 nM) agonist[5][6].	
IC₅₀ & Target	mAChR3	mAChR4
In Vitro	Clozapine N-oxide (CNO) can bind to non-DREADD receptors at concentrations required for DREADD activation, and undergoes reverse-metabolism to its parent compound clozapine, an atypical antipsychotic that acts at a variety of pharmacological targets and produces numerous physiological and behavioral effects[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
In Vivo	After a single intraperitoneal (i.p.) injection of Clozapine N-oxide (1 mg/kg) into mice, Clozapine N-oxide (CNO) plasma levels peak at 15 min and are very low after 2 h. Despite the short plasma half-life of CNO in mice, the biological effects that have been described after acute treatment of DREADD-expressing experimental animals are usually much longer (6-10 h)[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.	

CUSTOMER VALIDATION

- Cell Metab. 2022 Feb 1;34(2):285-298.e7.
- Nat Neurosci. 2023 Apr;26(4):542-554.
- Nat Commun. 2023 Apr 17;14(1):2182.
- Nat Commun. 2022 Apr 25;13(1):2233.
- Nat Commun. 2020 Nov 27;11(1):6045.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. Wess J, et al. Novel designer receptors to probe GPCR signaling and physiology. Trends Pharmacol Sci. 2013 Jul;34(7):385-92.
- [2]. Silva RR, et al. Evaluation of Functional Selectivity of NSC 170973, Clozapine, and LASSBio-579, an Experimental Compound With Antipsychotic-Like Actions in Rodents, at G Protein and Arrestin Signaling Downstream of the Dopamine D2 Receptor. Front Pharmacol. 2019 Jun 4;10:628.
- [3]. Zorn SH, et al. Clozapine is a potent and selective muscarinic M4 receptor agonist. Eur J Pharmacol. 1994 Nov 15;269(3):R1-2.
- [4]. Manvich DF, et al. The DREADD agonist clozapine N-oxide (CNO) is reverse-metabolized to clozapine and produces clozapine-like interoceptive stimulus effects in rats and mice. Sci Rep. 2018 Mar 1;8(1):3840.
- [5]. van der Peet PL, et al. Gram scale preparation of clozapine N-oxide (CNO), a synthetic small molecule actuator for muscarinic acetylcholine DREADDs. MethodsX. 2018 Mar 23;5:257-267.
- [6]. Joseph Cichon, et al. Branch-specific dendritic Ca(2+) spikes cause persistent synaptic plasticity. Nature. 2015 Apr 9;520(7546):180-5.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA